Alkem MedTech to Acquire 55% Stake in Occlutech for €99.4 Mn

The transaction marks Alkem MedTech’s entry into the global structural heart devices segment.

Alkem MedTech, the medical devices arm of Alkem Laboratories, has executed a binding offer to acquire up to a 55% stake in Switzerland-based Occlutech Holding AG for €99.4 million (approximately ₹1,074 crore). The transaction marks Alkem MedTech’s entry into the global structural heart devices segment.

The acquisition, announced on Friday, is subject to statutory and regulatory approvals and is expected to be completed by June 2026. Upon completion, Alkem MedTech will hold a controlling stake in Occlutech, a company specializing in minimally invasive cardiac implants.

Founded in 2003, Occlutech develops and manufactures devices used in the treatment of congenital heart disease, stroke prevention, and heart failure. The company is currently the second-largest player in Europe and the third-largest globally in the minimally invasive cardiac implants segment. It operates manufacturing and research and development facilities in Germany and Turkey, maintains a global distribution hub in Sweden, and has clinical operations in the United States.

In calendar year 2025, Occlutech reported unaudited revenues of €49.4 million, reflecting a compound annual growth rate (CAGR) of 15.7% over the past three years. Approximately 85% of its revenues are generated from the European Union and the United States.

For Alkem MedTech, the transaction expands its portfolio beyond orthopaedic implants into cardiovascular devices, a segment characterized by high regulatory barriers and premium pricing dynamics. The company currently operates a robotic and automation-enabled manufacturing facility in Gujarat and has been expanding its presence in medical devices as part of Alkem Laboratories’ broader diversification strategy.

B N Singh, Executive Chairman of Alkem Laboratories, said, “The acquisition of Occlutech opens up significant opportunities for Alkem MedTech and reinforces Alkem’s long-term vision of becoming a global player in the medical devices industry.”

Kaustav Banerjee, Chief Executive Officer of Alkem MedTech, stated that the acquisition provides entry into high-value markets, including the United States, Japan, Germany, and other Western European countries.

The deal remains subject to the signing of definitive agreements, fulfillment of conditions precedent, foreign investment control approvals in certain jurisdictions, and the absence of material adverse events. Boston Consulting Group acted as adviser to the transaction.

Stay tuned for more such updates on Digital Health News